Citius Pharmaceuticals, Inc., a biopharmaceutical company developing and commercializing first-in-class critical care products, and TenX Keane Acquisition a special purpose acquisition company (SPAC), have entered into a definitive agreement for a proposed merger of TenX and Citius Pharma’s wholly owned oncology subsidiary. The transaction is anticipated to close 1H24. The newly combined public company will be named Citius Oncology, Inc. and upon closing, Citius Pharma will receive 67.5...